Biomx Ltd (PHGE) |
|
7.54 -0.53 (-6.57%)
|
03-05 09:16 |
|
Open: |
8.03 |
Pre. Close: |
8.07 |
|
High:
|
8.03 |
Low:
|
7.35 |
|
Volume:
|
42,350 |
Market Cap:
|
175M |
|
|
|
|
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp). |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.033 - 8.087 |
8.087 - 8.132 |
|
Low:
|
7.253 - 7.302 |
7.302 - 7.343 |
|
Close:
|
7.466 - 7.548 |
7.548 - 7.616 |
|
Technical analysis |
as of: 2021-03-05 8:51:02 AM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 9.36  One year: 10.57 |
| Support: |
Support1: 6.34 Support2: 5.27 |
| Resistance: |
Resistance1: 8.01 Resistance2: 9.05 |
| Pivot: |
7.67  |
| Moving Average: |
MA(5): 7.86 MA(20): 7.47
MA(100): 6.47 MA(250): 6.24 |
| MACD: |
MACD(12,26): 0.32 Signal(9): 0.32 |
| Stochastic oscillator: |
%K(14,3): 55.61 %D(3): 56.52 |
| RSI: |
RSI(14): 51.75 |
| 52-week: |
High: 10.65 Low: 4.52 Change(%): -23.7 |
| Average Vol(K): |
3-Month: 6292 10-Days: 11452 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.PHGE has closed above bottom band by 43.5%. Bollinger Bands are 112.3% wider than normal. The large width of the bands suggest high volatility as compared to PHGE's normal range. The bands have been in this wide range for 11 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Tue, 02 Mar 2021
What is the Market's View on Biomx Inc (PHGE) Stock's Price and Volume Trends Tuesday? - InvestorsObserver
Tue, 02 Mar 2021
BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin - Business Wire
Mon, 01 Mar 2021
BiomX to Present at Upcoming March Investor Conferences - Business Wire
Mon, 22 Feb 2021
Biomx Inc (PHGE) Stock:Do Analysts Think You Should Buy? - InvestorsObserver
Mon, 22 Feb 2021
BiomX Inc.: Clinical Stage Phage Therapeutics Company Looks Promising - Seeking Alpha
Tue, 16 Feb 2021
Do Analysts Expect Biomx Inc (PHGE) Stock to Rise? - InvestorsObserver
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
23 |
| Shares Float (M) |
15 |
|
% Held by Insiders
|
18.25 |
|
% Held by Institutions
|
26.24 |
|
Shares Short (K)
|
23 |
|
Shares Short P. Month (K)
|
28 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-27.9 |
|
Return on Equity (ttm)
|
-46.0 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-1.141 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-23 |
|
Levered Free Cash Flow (M)
|
-16 |
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
|
|
Price to Cash Flow
|
-7.57 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
